Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia

This study is testing whether a combination of a drug that enhances brain signaling (NMDA-enhancing treatment) with an anti-inflammatory drug can improve symptoms in people with treatment-resistant schizophrenia. **You may be eligible if:** - You have a confirmed diagnosis of schizophrenia (as per DSM-5 criteria) - Your symptoms have not improved despite trying at least two different antipsychotic medications - You still have significant symptoms, but your condition has been stable for at least 3 months - Your antipsychotic dose has not changed in at least 3 months - You are willing to participate and can give informed consent **You may NOT be eligible if:** - You have an intellectual disability or active substance use disorder - You have a history of epilepsy, significant head injury, stroke, or other serious brain conditions - You have significantly abnormal blood or laboratory test results - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.